This is a working overview of 体积排阻色谱, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-25 and is reviewed periodically as new material appears.
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集，这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限，超出标签条件的稳定性仍属开放问题，需要在具体制剂中通过实时与加速试验加以确认。
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
| Property | Value | Notes |
|---|---|---|
| 保存温度 | 2 至 8 摄氏度 | 避免冻结，部分制剂允许短期室温 |
| 粉末外观 | 白色至类白色固体 | 吸湿后易结块 |
| 纯度检测方法 | 反相高效液相色谱 | 紫外检测，常用 214 纳米 |
| 分子量确认方法 | 液相色谱串联质谱 | 偏差通常以 ppm 表示 |
| 常见降解产物 | 氧化与脱酰胺变体 | 源自甲硫氨酸与天冬酰胺残基 |
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
In other words, the lack of positive support and validation increases the risk for divorce. Because of the expansive research done on the significance of social support within a marriage, it is important to understand that this research was inspired by a theory called the attachment theory perspective. Attachment theory stresses the importance of support and care giving in a relationship for the development of trust and security. Attachment theory, as conceptualized by Collins and Feeney (2000) is an interpersonal, transactional process that involves one partners caregiving responses.
=== Pest control === Chemical ecology has been utilized in the development of sustainable pest control strategies. Semiochemicals (especially insect sex pheromones) are widely used in integrated pest management for surveillance, trapping and mating disruption of pest insects. Unlike conventional insecticides, pheromone-based methods of pest control are generally species-specific, non-toxic and extremely potent. In forestry, mass trapping has been used successfully to reduce tree mortality from bark beetle infestations in spruce and pine forests and from palm weevils in palm plantations. In Australia, pheromone base trapping use was implemented to off set the use of pesticides due to the residues left behind in sheep wool. In an aquatic system, a sex pheromone from the invasive sea lamprey has been registered by the United States Environmental Protection Agency for deployment in traps. A strategy has been developed in Kenya to protect cattle from trypanosomiasis spread by Tsetse fly by applying a mixture of repellent odors derived from a non-host animal, the waterbuck. The use of sex pheromones depends on various factors such as concentration, ability to sense the pheromone, temperature, mixture of the pheromone with other compounds, and medium in which the pheromone is delivered, e.g. aquatic vs terrestrial. The successful push-pull agricultural pest management system makes use of chemical cues from intercropped plants to sustainably increase agricultural yields. The efficacy of push-pull agriculture relies on multiple forms of chemical communication.
In 1977, Sanger then adopted a primer-extension strategy to develop more rapid DNA sequencing methods at the MRC Centre, Cambridge, UK. This technique was similar to his "Plus and Minus" strategy, however, it was based upon the selective incorporation of chain-terminating dideoxynucleotides (ddNTPs) by DNA polymerase during in vitro DNA replication. Sanger published this method in the same year. Gilbert's interest in DNA sequencing arose from studies of gene regulation, particularly the lac operon. The method represented one of the first practical techniques for rapid DNA sequencing and earned Gilbert and Frederick Sanger the 1980 Nobel Prize in Chemistry for their independent contributions to nucleic acid sequencing.
Oxide mixtures: SiO2, Al2O3; MgO, SiO2; CaO, SiO2 Mounted bases: LiCO3 on silica; NR3, NH3, KNH2 on alumina; NaOH, KOH mounted on silica on alumina Inorganic chemicals: BaO, KNaCO3, BeO, MgO, CaO, KCN Anion exchange resins Charcoal that has been treated at 900 degrees Celsius or activates with N2O, NH3, ZnCl2-NH4Cl-CO2 Depending on a solid surface's ability to successfully form a conjugate base by absorbing an electrically neutral acid, basic strength of the surface is determined. The "number of basic sites per unit surface area of the solid" is used to express how much basic strength is found on a solid base catalyst. Scientists have developed two methods to measure the amount of basic sites: one, titration with benzoic acid using indicators and gaseous acid adsorption. A solid with enough basic strength will absorb an electrically neutral acidic indicator and cause the acidic indicator's color to change to the color of its conjugate base. When performing the gaseous acid adsorption method, nitric oxide is used. The basic sites are then determined by calculating the amount of carbon dioxide that is absorbed.
Sources: en.wikipedia.org
== External links == World Anti-Doping Agency v. Thomas Bellchambers et al., Australian Football League, Australian Sports Anti-Doping Authority — Arbitral Award delivered by the Court of Arbitration for Sport Essendon Football Club v Chief Executive Officer of the Australian Sports Anti-Doping Authority (19 September 2014) [2014] FCA 1019 Hird v Chief Executive Officer of the Australian Sports Anti-Doping Authority (9 October 2014) [2014] FCA 1090 Hird v Chief Executive Officer of the Australian Sports Anti-Doping Authority (includes Summary) (30 January 2015) [2015] FCAFC 7 Hird v Chubb Insurance Company of Australia Ltd (3 May 2016) [2016] VSC 174 "Timeline: Essendon doping investigation: timeline". ABC News (Australian Broadcasting Corporation). 27 August 2013. Retrieved 21 August 2015. "Essendon Bombers out of 2013 AFL finals as James Hird accepts 12-month suspension". ABC Grandstand Sport (Australian Broadcasting Corporation. 27 August 2013. Retrieved 21 August 2015. "AFL announces Essendon out of this year's finals series, Hird banned and club fined $2 million". Herald Sun. Fox Sports Australia. 27 August 2013. Retrieved 21 August 2015. "The Essendon supplements saga – a full timeline of quotes". AFL.com.au website. 27 August 2013. Retrieved 21 August 2015.
=== Targeted drug delivery systems === Targeted drug delivery systems facilitate the selective delivery of therapeutic agents to specific disease sites while minimizing off-target effects. These systems employ strategies, such as nanoparticles, liposomes, and micelles, to encapsulate drugs and enhance their stability, solubility, and bioavailability. By incorporating diagnostic components, such as imaging agents or targeting ligands, into these delivery systems, clinicians can monitor drug distribution and accumulation in real-time, ensuring effective treatment and reducing systemic toxicity. Targeted drug delivery systems hold promise in the treatment of cancer, cardiovascular diseases, and other conditions, as they allow for personalized and site-specific therapy.
During the fall of 1924, Marvel found him a job as an assistant biochemist at the Philadelphia General Hospital that helped him to teach clinical chemistry at the Graduate School of Medicine, University of Pennsylvania. Marvel would pay for the trip to Pennsylvania in exchange for du Vigneaud's preparation of 10 pounds of cupferron. Resuming his academic career in 1925, du Vigneaud joined the group of John R. Murlin at the University of Rochester for his PhD thesis. He graduated in 1927 with his work The Sulfur of Insulin. After a post-doctoral position with John Jacob Abel at Johns Hopkins University Medical School (1927–1928), he traveled to Europe as a National Research Council Fellow in 1928–1929, where he worked with Max Bergmann and Leonidas Zervas at the Kaiser Wilhelm Institute for Leather Research in Dresden, and with George Barger at the University of Edinburgh Medical School. He then returned to the University of Illinois as a professor. In 1932, he started working at the George Washington University Medical School in Washington, D.C., and in 1938, he attended the Cornell Medical College in New York City, where he stayed until his emeritation in 1967. Following retirement, he held a position at Cornell University in Ithaca, New York. In 1974, du Vigneaud had a stroke which forced his retirement. He died in 1978, one year after his wife's death in 1977.
The 2013 annual aggregate manufacturing quota is 250 kilos. International treaties and the controlled-substances laws of most countries, such as the German Betäubungsmittelgesetz, regulate dihydrocodeine at the same level as codeine. Dihydrocodeine-based pharmaceuticals are especially used where chronic pain patients are able to have essentially OTC access to them provided they are registered with the provincial or national government as such a patient. Controlled-release dihydrocodeine is a non-prescription item in some places, especially the 60 mg strength. A report by the Ivo Šandor Organisation in 2004 listed Andorra, Spain, Gibraltar and Austria as having varying degrees of access to these and other dihydrocodeine, nicocodeine and codeine products.
==== Freeze-drying ==== Freeze-drying, also known as freeze-casting or ice-templating, offers an alternative to the high temperature and high-pressure requirements of supercritical drying. Additionally, freeze-drying offers more control of the solid structure development by controlling the ice crystal growth during freezing. In this method, a colloidal dispersion of the aerogel precursors is frozen, with the liquid component freezing into different morphologies depending on a variety of factors such as the precursor concentration, type of liquid, temperature of freezing, and freezing container. As this liquid freezes, the solid precursor molecules are forced into the spaces between the growing crystals. Once completely frozen, the frozen liquid is sublimed into a gas through lyophilization, which removes much of the capillary forces, as was observed in supercritical drying. Though typically classified as a "cryogel", aerogels produced through freeze-drying often experience some shrinkage and cracking while also producing a non-homogenous aerogel framework. This often leads to freeze-drying being used for the creation of aerogel powders or as a framework for composite aerogels.
Sources: en.wikipedia.org
冻融过程中冰晶形成与局部浓度升高会促使肽链发生界面吸附和聚集。聚集不仅降低有效含量，还会改变可见异物与不溶性微粒的计数结果。将溶液分装为单次使用的小体积等份可减少循环次数。
该方法依据疏水性差异分离主峰与相关杂质，对缺失序列、氧化产物和脱酰胺变体具有较好分辨能力。流动相中加入离子对试剂可改善峰形。紫外检测在肽键吸收区工作，灵敏度足以支持常规放行检验。
加速条件可以放大多数化学降解，但聚集与界面诱导的变化对容器、摇动和温度历史更敏感。某些固态转变在短时高温下不一定出现。因此实时稳定性数据仍不可替代，加速结果一般只作为趋势参考。
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.